<DOC>
	<DOCNO>NCT00001427</DOCNO>
	<brief_summary>The objective study determine response rate 9-AC patient advanced ovarian cancer recurrent disease paclitaxel- cisplatin-based chemotherapy regimen .</brief_summary>
	<brief_title>A Phase II Trial 72-Hour Continuous IV Infusion 9-Aminocamptothecin With G-CSF Support Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel Cisplatin</brief_title>
	<detailed_description>This Phase II study 9-aminocamptothecin ( 9-AC ) , administer intravenous continuous infusion 72 hour G-CSF support patient advance refractory ovarian cancer . The objective present study determine response rate 9-AC patient advanced ovarian cancer recurrent disease paclitaxel- cisplatin-based chemotherapy regimen .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>9-aminocamptothecin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , advance epithelial ovarian cancer . Histologic confirmation Pathology Department , NIH , require . Recurrent disease paclitaxel either cisplatin carboplatin . Combination platinum/paclitaxel acceptable . Bidimensionally measurable disease physical exam , radiograph , peritoneoscopy . Repeat peritoneoscopy 8 course therapy require documentation disease solely peritoneoscopy . Laparotomy require . No CNS metastasis . No borderline mixed histology . PRIOR/CONCURRENT THERAPY : See Disease Characteristics . More 4 week since prior therapy recover . No prior camptothecin analoguebased chemotherapy . No prior radiotherapy except intraperitoneal 32P . PATIENT CHARACTERISTICS : Age : 18 . Performance status : ECOG 02 . Hematopoietic : WBC great 3,000 . AGC great 1,500 . Platelets least 100,000 . Hemoglobin great 9 g/dL OR ; Hematocrit great 27 g/dL . Hepatic : Bilirubin great 1.5 mg/dL . Serum transaminases great 2 time normal . Renal : 24hour creatinine clearance great 45 mL/min ( document NCI investigator primary care physician ) . Cardiovascular : No myocardial infarction within 12 month . No active congestive heart failure . No heart block . No arrhythmia require medication . OTHER : No active uncontrolled infection . No known HIV positivity . No second malignancy currently treatment except : Local basal cell carcinoma skin , Cervical carcinoma situ , Other malignancy ( e.g. , stage I breast cancer ) eligible discretion principal associate investigator . No pregnant woman .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Pharmacodynamic Studies</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>